SCHEMBL13684166

SCHEMBL13684166

CNS(=O)(=O)c1ccc(Cl)c(C(=O)C(C)(C)C)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSTO1 P78417 1/20 0.43
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA3 P07451 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA13 Q8N1Q1 1/20 0.36
CA14 Q9ULX7 1/20 0.36
CA5B Q9Y2D0 1/20 0.36
WDR5 P61964 1/20 0.36
PTGES2 Q9H7Z7 1/20 0.35
VCAM1 P19320 1/20 0.35
CYP1A2 P05177 1/20 0.35
KMT2A Q03164 1/20 0.35
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13684165 0.86 NSD2 (0.38) WDR5KMT2AALDH1A1LMNAMAPT
SCHEMBL3527829 0.84 GSTO1 (0.44) GSTO1CA12CA1CA2CA3
SCHEMBL13545101 0.84 GSTO1 (0.44) GSTO1CA12CA1CA2CA3
SCHEMBL13542947 0.82 CA1 (0.38) CA12CA1CA2CA3CA4
SCHEMBL13542992 0.80 GSTO1 (0.42) GSTO1CA12CA1CA2CA3
SCHEMBL13950348 0.80 GSTO1 (0.45) GSTO1CA12CA1CA2CA3
SCHEMBL6766698 0.76 PKM (0.45) GSTO1CA12CA1CA2CA3
SCHEMBL13543283 0.75 GSTO1 (0.52) GSTO1CA1CA2CYP1A2KMT2A
SCHEMBL4030951 0.73 WDR5 (0.50) GSTO1CA12CA1CA2CA3
SCHEMBL13542948 0.72 ALDH1A1 (0.36) CA12CA1CA2CA3CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589204-B2 Indane compounds as CCR5 antagonists SMITHKLINE BEECHAM CORPORATION (US) 2009-09-15 US disclosed
US-7589204-B2 Indane compounds as CCR5 antagonists SMITHKLINE BEECHAM CORPORATION (US) 2009-09-15 US disclosed
US-20090053172-A1 HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS AQUINO CHRISTOPHER JOSEPH 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090053172-A1 HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS CCR5, CXCR3, CCR1 GSTO1 3953/4885CA12 4870/4885CA1 4865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.